Skip to content
Sharism- Lifestyle
Author:
HUTCHMED (China) Limited
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
March 26, 2026
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
March 22, 2026
←
Previous Page
1
2